Boenning & Scattergood Initiates Coverage on Array BioPharma (ARRY)
More News related to ARRY
- UBS Upgrades Array BioPharma (ARRY) to Buy
- Array BioPharma (ARRY) Reports Q1 Loss of $0.52, Beats by 3c
- Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2010
- Array BioPharma to Report Financial Results for the First Quarter of Fiscal 2010 on November 2, 2009
- Array BioPharma to Present Clinical Results on Diabetes Drug at European Diabetes Meeting
Boenning & Scattergood initiates coverage on Array BioPharma (Nasdaq: ARRY) with an Outperform rating. Price target $6.
To see more analyst ratings on ARRY Click Here.
Array BioPharma Inc. (Array) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs.
Related Categories
New CoverageStocks Mentioned
-0.02Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
